Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 9/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 3/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | ACE | P12821 | 2/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL7646190 | 0.93 | CTSK (0.37) | RENCTSKBCHEMMEECE1 | |
| SCHEMBL5058010 | 0.79 | EPHX2 (0.44) | MMEEPHX2ACECPA1ACE2 | |
| SCHEMBL5051299 | 0.78 | CNR2 (0.46) | CTSKMMEECE1ACECPA1 | |
| SCHEMBL5053032 | 0.76 | GGH (0.47) | MME | |
| SCHEMBL5054738 | 0.74 | POLB (0.48) | MMEACECPA1ACE2 | |
| SCHEMBL5054288 | 0.71 | LTA4H (0.47) | MMEECE1ACE | |
| SCHEMBL5051224 | 0.69 | LTA4H (0.50) | CTSKMMEEPHX2ACECPA1 | |
| SCHEMBL5053356 | 0.68 | GGT1 (0.46) | MME | |
| SCHEMBL5060126 | 0.67 | GGH (0.55) | — | |
| SCHEMBL5059968 | 0.67 | S1PR2 (0.47) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1044206-A1 | PRODRUGS OF NAALADASE INHIBITORS | Guildford Pharmaceuticals Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999033849-A1 | PRODRUGS OF NAALADASE INHIBITORS | GUILDFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |